We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment.
- Authors
Lahner, E.; Bordi, C.; Di Giulio, E.; Caruana, P.; D'Ambra, G.; Milione, M.; Grossi, C.; Delle Fave, G.; Annibale, B.
- Abstract
Background: It has been reported that 50% of patients with atrophic body gastritis have positive Helicobacter pylori antibody titres only. In atrophic body gastritis, a decrease in H. pylori antibodies after eradication treatment has been reported, suggesting that serology may indicate an active H. pylori infection. Aim: To investigate the time course of H. pylori antibodies and gastric inflammation after eradication treatment in patients with atrophic body gastritis, and to determine whether serology alone can be considered as a valid tool to assess the efficacy of eradication treatment in patients with atrophic body gastritis. Methods: Twenty-seven patients with atrophic body gastritis (12 serologically H. pylori -positive only, ABG-S+; 15 H. pylori -positive at histology and serology, ABG-H+) were included in the treatment group, and 17 patients (all ABG-S+) in the no treatment group. All patients had gastroscopy plus biopsies evaluated according to the updated Sydney system and H. pylori immunoglobulin G determination: in the treatment group, at baseline and 6 and 24 months after eradication (bismuth-based triple regimens); in the no treatment group, at baseline and after 3 years. Results: In the treatment group, in ABG-S+ patients, H. pylori antibodies decreased significantly 6 months after treatment [37.5 U/mL (16–100 U/mL) vs. 15 U/mL (0–100 U/mL), P < 0.01], but 2 years after treatment no further decrease occurred. In addition, in ABG-H+ patients, a significant decrease in H. pylori antibodies occurred 6 months after treatment [45 U/mL (12.5–100 U/mL) vs. 31 U/mL (0–65 U/mL), P < 0.01], but a further decrease was also observed 2 years after treatment [20 U/mL (0–56 U/mL), P < 0.01]. In ABG-S+ patients, no correlation was observed between the H. pylori antibodies and gastric inflammation score, whereas, in the ABG-H+ group, this correlation was extremely significant (r =0.5991, P < 0.0001). In the no treatment group, at...
- Subjects
HELICOBACTER pylori; GASTRITIS; SEROLOGY
- Publication
Alimentary Pharmacology & Therapeutics, 2002, Vol 16, Issue 3, p507
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1046/j.1365-2036.2002.01213.x